Exciting news! Earlier today, the U.S. Food & Drug Administration announced the approval of ozanimod (Zeposia®), a new oral medication for the treatment of adults with moderately-to-severely active ulcerative colitis. Ozanimod is the first sphingosine 1-phosphate (S1P) receptor modulator approved for IBD and a new mechanism of action for treatment of UC.
FDA Approves Ozanimod for Adults with Ulcerative Colitis
The treatment is also being studied for safety and efficacy in patients with Crohn’s disease.
www.hcplive.com